Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01598896 · ClinicalTrials.gov registry record · Phase 2
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
A Phase 2 study, sponsored by Mclean Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01598896 is a Phase 2 study that was terminated before completion, run by Mclean Hospital. The registered enrollment target is 12 participants.
The verdict
NCT01598896, a Phase 2 study, was terminated before completion, sponsored by Mclean Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Cannabis use disorders are an important public health problem in the United States, but no effective pharmacotherapies are available to treat these disorders. People with schizophrenia are more likely than healthy people to abuse cannabis. Cannabis use may worsen clinical outcomes in this group, making the identification of pharmacotherapy to treat cannabis dependence in those with schizophrenia important. The investigators intend to test the combination of dronabinol, a cannabinoid agonist, and the α2-adrenergic agonist clonidine, for cannabis dependence in subjects with schizophrenia. The combination of dronabinol and clonidine may alleviate cannabis withdrawal symptoms while allowing treatment-seeking outpatients to benefit from medical management (MM) sessions when they are trying to stop using cannabis. The investigators propose to assess the relationship of dronabinol and clonidine, when added to MM, on cannabis use patterns in cannabis-dependent patients with schizophrenia. Hypothesis: The investigators predict that combination pharmacotherapy of dronabinol and clonidine will significantly reduce cannabis use compared to those receiving placebo.
Interventions
- DRUG Placebo
- DRUG Dronabinol
- DRUG Clonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-05 |
| Est. Completion | 2017-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01598896
The ClinicalTrials.gov registry entry for NCT01598896 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01598896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01598896 about?
NCT01598896 is a clinical study titled "Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia". Cannabis use disorders are an important public health problem in the United States, but no effective pharmacotherapies are available to treat these disorders. People with schizophrenia are more likely than healthy people to abuse cannabis. Cannabis use may worsen clinical outcomes in this group, mak...
What is the current status of trial NCT01598896?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2012-05. Estimated completion is 2017-08.
What interventions are being tested in trial NCT01598896?
The interventions under investigation include: Placebo (DRUG), Dronabinol (DRUG), Clonidine (DRUG).
Who is sponsoring clinical trial NCT01598896?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.